Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CASP1
REST API REST API
Homo sapiens
CASP1 is differentially expressed in 359 experiments: 145 organism parts: lung, bone marrow, ... (143 more);, 257 disease states: normal, glioblastoma, ... (255 more);, 151 cell types 547 cell lines 46 compound treatments and 74 other conditions.
Synonyms ICE, IL1BC
Orthologs caspb (Danio rerio)   F1P0X7_CHICK (Gallus gallus)   zgc:171731 (Danio rerio)   caspa (Danio rerio)   CU896655.3 (Danio rerio)   Casp1 (Mus musculus)   ENSCING00000008214 (Ciona intestinalis)   Casp1 (Rattus norvegicus)   Nc (Drosophila melanogaster)   si:ch211-15j1.6 (Danio rerio)   casp1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, memory, intracellular, innate immune response, response to toxin, response to chemical stimulus, myoblast fusion, peptidase activity, activation of caspase activity, extracellular region, response to hypoxia, positive regulation of apoptosis, midgut development, induction of apoptosis, cysteine-type endopeptidase activity, nucleus, protein processing, caspase activator activity, response to lipopolysaccharide, cell death, response to drug, proteolysis, signal transduction, cysteine-type peptidase activity, regulation of apoptosis, positive regulation of I-kappaB kinase/NF-kappaB cascade, positive regulation of interleukin-1 beta secretion, cellular response to mechanical stimulus, activation of innate immune response, positive regulation of interleukin-1 alpha secretion, positive regulation of circadian sleep/wake cycle, non-REM sleep, positive regulation of cytokine secretion, response to ATP, lung development, cellular response to organic substance, microglial cell activation, response to organic cyclic compound, interleukin-1 beta production
InterPro Term Pept_C14_p10, Pept_C14_ICE_p20, Pept_C14_p45_core, Pept_C14_cat, Caspase_IL-1_beta, CARD
UniProt Accession P29466, B4DVD8, Q5FBZ0
Search EB-eye ENSG00000137752
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-19397, ... (47 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
Jurkat
2
E-MEXP-2197, E-GEOD-1880
KG1
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF-7
2
E-GEOD-5823, E-GEOD-20081
541 more value(s).


Cell type

studied in E-MEXP-750, E-GEOD-20677, E-TABM-34, E-GEOD-2822, E-GEOD-21909, ... (67 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-19240, E-GEOD-96, E-GEOD-3998
human embryonic stem cell
3
E-GEOD-18265, E-GEOD-18147, E-GEOD-20033
CD4+ T cell
2
E-MEXP-1600, E-AFMX-5
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
145 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-12254, E-TABM-15, E-GEOD-16363, ... (74 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-GEOD-1729, E-GEOD-96
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
glioblastoma
2
4
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MEXP-567, E-GEOD-6014, ... (6 experiments)
astrocytoma
2
E-MTAB-37, E-GEOD-4290
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MEXP-66, E-MTAB-62
251 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-5542, E-GEOD-697, E-TABM-782, E-GEOD-3720, ... (28 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-3920
lipopolysaccharide
1
2
E-GEOD-3720, E-TABM-868, E-MEXP-1958
control - untreated
1
E-GEOD-4984
unknown
1
E-GEOD-7307
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
40 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Chromosomal aberration
studied in E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-5764, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1493, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-21521

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Processing time: 0.502 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM